Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Perampanel, ATC N03AX22 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. Verlängerungsoption 1x12 Monate)

Section 130a (8) of the German Social Code (SGB V) enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the German Competition Act (GWB) is carried out by the DAK-Gesundheit. For the medicines to be specified by the bidder in Annex 2 to the contract for the aforementioned substance Perampanel, ATC N03AX22, the DAK-Gesundheit intends to conclude discount contracts for medicines with as many interested pharmaceutical companies as possible until the entry into force of new drug discount contracts. A discount contract under the approval model for the aforementioned substance will come into force for the first time on 01.09.2026 and will end on 31.08.2028 (plus extension option 1x12 months). It will automatically end, regardless, with the entry into force of the exclusive contract.